Company attributes
Other attributes
SEngine Precision Medicine is a precision medicine company that develops personalized cancer treatment testing and cancer therapeutics. The company was established by Brady Bernard, Carla Grandori, Christopher Kemp, VK Gadi in 2015, and was spunned out from Fred Hutchinson Cancer Research Center. SEngine Precision Medicine has received funding from Bangarang Group and a grant from National Health Institute. It is headquartered in Seattle, Washington, United States.
PARIS is a test to determine which cancer therapeutics would be suitable for an individual patient. This is done through a DNA-based functional drug testing on the patient's tumor sample. PARIS would generate an individual genomic profile based on the input, and assess which therapeutics are recommended for the patient with the least side-effects.
SEngine Precision Medicine partners with pharmaceutical companies to develop oncology drugs. It uses a proprietary computational drug discovery platform to generate compounds. The company is aiming at creating therapeutics that can inhibit gene alterations in MYC, TP53, and KRASC.
